Patent 5942253 Issued on August 24, 1999. Estimated Expiration Date: October 12, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.
Other References
Benita, et al., "Characterization of Drug-Loaded Poly(d,-lactide) Mirospheres," J. Pharm. Sci., 73:1721-1724 (1984)
Braunstein et al., "GM-CSF Activates Regenerative Epidermal Growth and Stimulates Keratinocyte Proliferation in Human Skin In Vivo", J. Invest. Dermatol., 103:601-604 (1994)
Grabstein, et al., "Regulation of Antibody Production In Vitro by Granulocyte-Macrophage Colony Stimulating Factor",J. Mol. Cell. Immunol., 2:199-207 (1986)
Lim, et al., "Microencapsulation of Living Cells and Tissues," J. Pharm. Sci., 70:351-354 (1981)
Lu and Park, "Protein Release from Poly(lactic-co-glycolic acid) Micropheres: Protein Stability Problems," J. Pharm, Sci. Technical, 49:13-19 (1995)
Mathiowitz and Langer, "Polyanhydride Microspheres as Drug Carriers. I. Hot-Melt Microencapsulation," J. Controlled Release, 5:13-22 (1987)
Mathiowitz, et al., "Novel Microcapsules for Delivery Systems," Reactive Polymers, 6:275-283 (1987)
Mathiowitz, et al., Polyanhydride Microspheres as Drug Carriers. II. Microencapsulation by Solvent Removal, J. Appl. Polymer Sci., 35:755-774 (1988)
Mathiowitz, et al., "Morphology of Polyanhyfride Microsphere Delivery Systems", Scanning Mircoscopy, 4:329-340 (1990)
Mathiowitz, et al., "Polyanhydride Microspheres.IV. Morphology and Characterization of Systems Made by Spray Drying", J. Appl. Polymer Sci., 45:125-134 (1992)
Morrissey, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments The Primary Antibody Response By Enhancing The Function Of Antigen-Presenting Cells," J. Immunology, 139:1113-1119 (1987)
HongKee Sah, et al., "The Influence of Biodegradable Microcapsule Formulations on the Controlled Release of A Protein," J. Controlled Release, 30:201-211 (1994)
Salib, et al., "Utilization of Sodium Alginate in Drug Microencapsulation," Pharmazeutische Industrie, 40(11A):1230-1234 (1978
October 12, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
